Profile data is unavailable for this security.
About the company
Syncona Limited is a Guernsey-based closed-ended investment company. The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.
- Revenue in GBP (TTM)5.65m
- Net income in GBP-17.55m
- Incorporated2012
- Employees0.00
- LocationSyncona Limited3Rd FloorArnold House, St Julian's AvenuePO Box 273SAINT PETER PORT GY1 3RDGuernseyGGY
- Websitehttps://www.synconaltd.com/
Profile
| Management group(s) | Syncona Investment Management Limited |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GG00B8P59C08 |
| Launch date | 26 Oct 2012 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. The Company invests in life science businesses and single or multi-asset projects. The Company targets an annualised return per share across its investment portfolio of 15 per cent per annum over the long term.
Managed by
| Chris Hollowood |
|---|
Management & contract fees
The company will pay SIML an annual fee of up to 1.05% p.a. of the NAV of company. The fee will be payable monthly in arrears and each payment shall be calculated using the monthly NAV as at the relevant month end.
Mergers & acquisitions
| Acquired company | SYNC:LSE since announced | Transaction value |
|---|---|---|
| Freeline Therapeutics Holdings PLC | -16.03% | 28.30m |
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Baillie Gifford Japan Trust PLC | 72.15m | 63.76m |
| Henderson Smaller Companies Inv Trst PLC | 100.37m | 93.35m |
| Bellevue Healthcare Trust PLC | -19.04m | -30.45m |
| Partners Group Private Equity Ltd | 51.23m | 19.18m |
| Molten Ventures PLC | 2.70m | -5.90m |
| Brunner Investment Trust Plc | 109.30m | 103.52m |
| Syncona Ltd | 5.65m | -17.55m |
| GCP Infrastructure Investments Ltd | 36.08m | 15.07m |
| BlackRock Smaller Companies Trust plc | 133.64m | 125.78m |
| VinaCapital Vietnam Opportunity Fund Ltd | 79.32m | 57.93m |
| Edinburgh Worldwide Investment Trust plc | -75.55m | -87.03m |
| Cordiant Digital Infrastructure Ltd | 99.86m | 80.30m |
| Schroder Oriental Income Fund Ltd | 125.47m | 110.40m |
| European Smaller Companies Trust PLC | 97.52m | 84.90m |
| Asia Dragon Trust PLC | -36.25m | -46.86m |
| JPMorgan Indian Investment Trust plc | 142.43m | 114.31m |
